For the coming 5 years, the company is firmly insisting on the R&D strategy of ‘innovation first within the development of generic drugs’. The R&D is based on the funding support, supported by talents introduction, and ensured by system establishment. Therefore, the R&D centre keeps promoting the quality and level of research projects, tries to find out a sustainable innovation development pathway, which is suitable for current Sanhome, and eventually makes innovation become the motivation source of Sanhome’s development.
The company is going to increase the investment on R&D. To establish a good material foundation for innovation, the input to R&D is planning to be maintained at 8% or above of the total sales income. More high-level talents will be continually introduced to Sanhome and the scientists’ team building will be reinforced. Through a good-quality training process, a high quality R&D team will then be established. By comprehensive salary models, including equity, excellent environmental and intellectual support could then be set for innovation. By further perfecting the innovation system, establishing the innovation platform, and setting a higher start-point for innovation, more powerful support can be then guaranteed to the continuing innovation and development.
(1) Selection of R&D direction
Sanhome is mainly focusing on originally innovative drugs, due consideration to me-too and me-better innovations. Fast imitation to selective drugs to become the first imitation.
Fast development on bio-pharmaceutics, while keeping steady development on small molecular drugs.
(2) R&D strategy
In combine with independent innovation, investment could also be adopted by merging other R&D centres to acquire the ownership of the others’ products.